CHIR-99021 (Laduviglusib)

製品コードS1263 バッチS126310

印刷

化学情報

Synonyms

CT99021

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₂₂H₁₈Cl₂N₈

分子量

465.34

CAS No.

252917-06-9

Solubility (25°C)*

体外

DMSO

93 mg/mL (199.85 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.650mg/ml (1.40mM)	Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	ラドゥビグルシブ (Laduviglusib (CHIR-99021、CT99021)) は GSK-3α および GSK-3β 阻害剤であり、IC50 はそれぞれ 10 nM および 6.7 nM です。ラドゥビグルシブは、サイクリン依存性キナーゼ (CDK) に対して交差反応性を示さず、CDK と比較して GSK-3β に対して 350 倍の選択性を示します。 Laduviglusib は Wnt/β-catenin 活性化因子として機能し、オートファジー (autophagy) を誘導します。
in vitro	CHIR-99021 (Laduviglusib) shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, it shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. This compound induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM^[1].
in vivo	Oral administration of CHIR-99021 (Laduviglusib) at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Given 1 hour before oral glucose challenges in ZDF rats at 16 or 48 mg/kg, it significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of this compound also reduces hyperglycemia before the oral glucose challenge^[1].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	Insulin receptor–expressing CHO-IR cells; Primary rat hepatocytes
	濃度	0.01-10 μM
	反応時間	30 min
	実験の流れ	CHO-IR cells expressing human insulin receptor are grown to 80% confluence in Hamm’s F12 medium with 10% fetal bovine serum and without hypoxanthine. Trypsinized cells are seeded in 6-well plates at 1 × 10⁶ cells/well in 2 ml of medium without fetal bovine serum. After 24 h, medium is replaced with 1 ml of serum-free medium containing CHIR-99021 (Laduviglusib) or control (final DMSO concentration <0.1%) for 30 min at 37°C. This compound is a GSK-3 inhibitor. Cells are lysed and centrifuged 15 min at 4°C/14000g. The activity ratio of GS is calculated as the GS activity in the absence of glucose-6-phosphate divided by the activity in the presence of 5 mmol/l glucose-6-phosphate, using the filter paper assay of Thomas et al.
動物実験	動物モデル	Female db/db mice; Male ZDF rats
	投薬量	8-48 mg/kg
	投与方法	oral administration

参考

https://pubmed.ncbi.nlm.nih.gov/12606497/

カスタマーフィードバック

: , , Dr. Yong-Weon Yi from Georgetown University Medical Center

: Data from [Data independently produced by , , Med Oncol, 2017, 35(1):7]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups [ Cancer Cell, 2025, 43(4):776-796.e14]	PubMed: 40185092
Olmesartan Restores LMNA Function in Haploinsufficient Cardiomyocytes [ Circulation, 2025, 151(20):1436-1448]	PubMed: 40166828
Olmesartan Restores LMNA Function in Haploinsufficient Cardiomyocytes [ Circulation, 2025, 151(20):1436-1448]	PubMed: 40166828
Structure-guided discovery of highly efficient cytidine deaminases with sequence-context independence [ Nat Biomed Eng, 2025, 9(1):93-108]	PubMed: 38831042
A continuous totipotent-like cell-based embryo model recapitulates mouse embryogenesis from zygotic genome activation to gastrulation [ Nat Cell Biol, 2025, NONE]	PubMed: 41094030
AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models [ Nat Commun, 2025, 16(1):2196]	PubMed: 40038304
LncRNA HSCHARME is altered in human cardiomyopathies and promotes stem cell-derived cardiomyogenesis via splicing regulation [ Nat Commun, 2025, 16(1):7880]	PubMed: 40849301
Non-invasive action potential recordings using printed electrolyte-gated polymer field-effect transistors [ Nat Commun, 2025, 16(1):8143]	PubMed: 40885735
Highly efficient construction of monkey blastoid capsules from aged somatic cells [ Nat Commun, 2025, 16(1):1130]	PubMed: 39875393
Chromatin interaction maps of human arterioles reveal mechanisms for the genetic regulation of blood pressure [ Nat Commun, 2025, 16(1):6577]	PubMed: 40675959

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。